SAN
DIEGO, June 20, 2023 /PRNewswire/ --
Cardiff Oncology, Inc. (Nasdaq: CRDF), a
clinical-stage biotechnology company leveraging PLK1 inhibition, a
well-validated oncology drug target, to develop novel therapies
across a range of cancers, today announced that
on June 20, 2023, non-qualified stock option awards to
purchase an aggregate of 40,032 shares of its common stock
were granted to one new employee. The stock options were
granted as inducements material to the new employee becoming an
employee of Cardiff Oncology in accordance with Nasdaq Listing Rule
5635(c)(4).
The options have an exercise price of $1.56 per share,
which is equal to the closing price of Cardiff Oncology's common
stock on June 20, 2023. Each option will vest over a 4-year
period, with 25% of the shares vesting upon the 1-year anniversary
of the date of grant and the remaining shares vesting monthly over
the following 36-months, subject to the employee's continued
employment with Cardiff Oncology on such vesting dates.
About Cardiff Oncology, Inc.
Cardiff Oncology is a
clinical-stage biotechnology company leveraging PLK1 inhibition, a
well-validated oncology drug target, to develop novel therapies
across a range of cancers. The Company's lead asset is onvansertib,
a PLK1 inhibitor being evaluated in combination with
standard-of-care (SoC) therapeutics in clinical programs targeting
indications such as KRAS/NRAS-mutated metastatic colorectal cancer
(mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as
well as in investigator-initiated trials in triple negative breast
cancer (TNBC) and small cell lung cancer (SCLC). These programs and
the Company's broader development strategy are designed to target
tumor vulnerabilities in order to overcome treatment resistance and
deliver superior clinical benefit compared to the SoC alone. For
more information, please
visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki
Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Richa
Kumari
Taft Communications
551 344-5592
richa@taftcommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-reports-inducement-grant-under-nasdaq-listing-rule-5635c4-301855960.html
SOURCE Cardiff Oncology, Inc.